Izalontamab SI-B001: A Promising Emerging Antibody Treatment
The drug SI-B001 is an significant advance in cancer care of refractory multiple myeloma. This first-in-class antibody specifically targets BCMA within myeloma tumors, triggering antibody-dependent cellular cytotoxicity or enhancing tumor-killing patient's reactions. Preliminary patient evidence